Literature DB >> 26839643

Cirrhotic cardiomyopathy: Isn't stress evaluation always required for the diagnosis?

Mara Barbosa1, Joana Guardado1, Carla Marinho1, Bruno Rosa1, Isabel Quelhas1, António Lourenço1, José Cotter1.   

Abstract

AIM: To describe the proportion of patients with cirrhotic cardiomyopathy (CCM) evaluated by stress echocardiography and investigating its association with the severity of liver disease.
METHODS: A cross-sectional study was conducted. Cirrhotic patients without risk factors for cardiovascular disease were included. Data regarding etiology and severity of liver disease (Child-Pugh score and model for end-stage liver disease), presence of ascites and gastroesophageal varices, pro-brain natriuretic peptide (pro-BNP) and corrected QT (QTc) interval were collected. Dobutamine stress echocardiography (conventional and tissue Doppler imaging) was performed. CCM was considered present when diastolic and/or systolic dysfunction was diagnosed at rest or after pharmacological stress. Therapy interfering with cardiovascular system was suspended 24 h before the examination.
RESULTS: Twenty-six patients were analyzed, 17 (65.4%) Child-Pugh A, mean model for end-stage liver disease (MELD) score of 8.7. The global proportion of patients with CCM was 61.5%. At rest, only 2 (7.7%) patients had diastolic dysfunction and none of the patients had systolic dysfunction. Dobutamine stress echocardiography revealed the presence of diastolic dysfunction in more 6 (23.1%) patients and of systolic dysfunction in 10 (38.5%) patients. QTc interval prolongation was observed in 68.8% of the patients and increased pro-BNP levels in 31.2% of them. There was no association between the presence of CCM and liver impairment assessed by Child-Pugh score or MELD (P = 0.775, P = 0.532, respectively). Patients with QTc interval prolongation had a significant higher rate of gastroesophageal varices comparing with those without QTc interval prolongation (95.0% vs 50.0%, P = 0.028).
CONCLUSION: CCM is a frequent complication of cirrhosis that is independent of liver impairment. Stress evaluation should always be performed, otherwise it will remain an underdiagnosed condition.

Entities:  

Keywords:  Cirrhosis; Cirrhotic cardiomyopathy; Corrected QT interval prolongation; Dobutamine stress echocardiography; Liver impairment

Year:  2016        PMID: 26839643      PMCID: PMC4724582          DOI: 10.4254/wjh.v8.i3.200

Source DB:  PubMed          Journal:  World J Hepatol


  37 in total

1.  Diastolic stress echocardiography: hemodynamic validation and clinical significance of estimation of ventricular filling pressure with exercise.

Authors:  Malcolm I Burgess; Carly Jenkins; James E Sharman; Thomas H Marwick
Journal:  J Am Coll Cardiol       Date:  2006-04-03       Impact factor: 24.094

2.  The cardiorenal link in advanced cirrhosis.

Authors:  Aleksander Krag; Flemming Bendtsen; Andrew K Burroughs; Søren Møller
Journal:  Med Hypotheses       Date:  2012-04-24       Impact factor: 1.538

Review 3.  Cardiac electrophysiological abnormalities in patients with cirrhosis.

Authors:  Andrea Zambruni; Franco Trevisani; Paolo Caraceni; Mauro Bernardi
Journal:  J Hepatol       Date:  2006-01-24       Impact factor: 25.083

Review 4.  Recommendations for the evaluation of left ventricular diastolic function by echocardiography.

Authors:  Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelista
Journal:  J Am Soc Echocardiogr       Date:  2009-02       Impact factor: 5.251

Review 5.  Cirrhotic cardiomyopathy.

Authors:  Søren Møller; Jens H Henriksen
Journal:  J Hepatol       Date:  2010-03-31       Impact factor: 25.083

6.  QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt.

Authors:  Franco Trevisani; Manuela Merli; Francesco Savelli; Valentina Valeriano; Andrea Zambruni; Oliviero Riggio; Paolo Caraceni; Marco Domenicali; Mauro Bernardi
Journal:  J Hepatol       Date:  2003-04       Impact factor: 25.083

7.  Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging.

Authors:  Konstantin Kazankov; Peter Holland-Fischer; Niels H Andersen; Peter Torp; Erik Sloth; Niels K Aagaard; Hendrik Vilstrup
Journal:  Liver Int       Date:  2011-02-15       Impact factor: 5.828

8.  Diastolic myocardial dysfunction does not affect survival in patients with cirrhosis.

Authors:  Alexandra Alexopoulou; George Papatheodoridis; Sophia Pouriki; Christina Chrysohoou; Leonidas Raftopoulos; Christodoulos Stefanadis; Dimitrios Pectasides
Journal:  Transpl Int       Date:  2012-08-21       Impact factor: 3.782

9.  Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis.

Authors:  Andrea Zambruni; Franco Trevisani; Antonio Di Micoli; Francesco Savelli; Annalisa Berzigotti; Eleonora Bracci; Paolo Caraceni; Marco Domenicali; Palmiro Felline; Marco Zoli; Mauro Bernardi
Journal:  J Hepatol       Date:  2007-12-26       Impact factor: 25.083

Review 10.  Diastolic failure: pathophysiology and therapeutic implications.

Authors:  D L Brutsaert; S U Sys; T C Gillebert
Journal:  J Am Coll Cardiol       Date:  1993-07       Impact factor: 24.094

View more
  3 in total

1.  Prevalence and clinical presentation of cirrhotic cardiomyopathy: A single centre experience from southern India.

Authors:  Ravi Bokarvadia; Mayank Jain; Chandankumar Kedarisetty; Joy Varghese; Jayanthi Venkataraman
Journal:  Indian J Gastroenterol       Date:  2019-05-21

Review 2.  Cirrhotic Cardiomyopathy: A New Clinical Phenotype.

Authors:  Luis Otávio Cardoso Mocarzel; Mariana Macedo Rossi; Bruna de Mello Miliosse; Pedro Gemal Lanzieri; Ronaldo Altenburg Gismondi
Journal:  Arq Bras Cardiol       Date:  2017-06       Impact factor: 2.000

3.  Systemic immunoglobulin light-chain amyloidosis presenting hematochezia as the initial symptom.

Authors:  Tetsuo Kon; Naoki Nakagawa; Fumitsugu Yoshikawa; Kazunao Haba; Nagako Kitagawa; Michihiro Izumi; Setsuo Kumazaki; Satoshi Ishida; Ryuichi Aikawa
Journal:  Clin J Gastroenterol       Date:  2016-06-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.